Physician profile
Timothy Mcbride
NPI 1013940923
$3,626.76
in general payments reported to CMS, 2019-2025
23 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $136 · 2021: $423 · 2022: $355 · 2023: $682 · 2024: $801 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,128.86 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $333.00 | 2021-2025 | |
| Novo Nordisk INC | $211.35 | 2023-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $171.66 | 2022-2025 | |
| Glaxosmithkline, LLC. | $157.41 | 2019-2023 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.04 | 2019-2024 | Jardiance, Synjardy |
| Lilly USA, LLC | $112.00 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $85.96 | 2019-2021 | |
| Pfizer INC. | $32.43 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $31.41 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.41 | 2022 | |
| Amgen INC. | $26.51 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.77 | 2024 | Lifevest |
| Esperion Therapeutics, INC. | $21.78 | 2020 | |
| Merck Sharp & Dohme LLC | $18.21 | 2025 | Capvaxive, Vaxneuvance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17.32 | 2024 | Intellis Adaptivestim |
| Exact Sciences Corporation | $16.60 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $13.46 | 2023 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $13.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.76 | 2021 | |
| Allergan, INC. | $12.18 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.74 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.